Arch Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Arch Therapeutics, Inc. Arch Therapeutics, Inc. (ARTH) is a development-stage biotechnology company focused on developing synthetic self-assembling peptide technology for hemostasis, liquid control, and wound management in surgery, trauma, and interventional care. The company offers the AC5 Advanced Wound System, authorized for marketing as a medical device in the United States for managing complex chronic and surgical wounds; the AC5 Topical Hemostat, cleared for use in Europe to control bleeding; and development-stage candidates including AC5 Surgical Hemostat for open and laparoscopic procedures, AC5-G, and AC5-V, all leveraging a proprietary platform that forms protective barriers without external energy to enhance patient safety and procedure efficiency. Founded in 2006 and headquartered in Framingham, Massachusetts, Arch Therapeutics primarily operates in the United States while pursuing international regulatory approvals and targets surgeons, trauma care providers, and interventional specialists with its Crystal Clear Surgery branded solutions that enable prophylactic bleeding control and maintain clear operative fields. Recent developments include the addition of a contract sales force in 2023 to accelerate commercialization of the AC5 Advanced Wound System in government facilities; receipt of a dedicated HCPCS billing code from the Centers for Medicare & Medicaid Services in March 2023 to facilitate reimbursement; completion of bridge financing in September 2023 as a step toward uplisting to a national exchange; and presentations of the AC5 Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall and Spring Meetings to advance clinical adoption and partnerships.
SANUWAVE Health (OTCMKTS:SNWV) and Arch Therapeutics (OTCMKTS:ARTH) Critical Review
Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
7 Stock Winners That Are Up 1,000% or More in 2023
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
Arch Therapeutics Provides AC5® Commercialization Update
Arch Therapeutics Completes Financing as Bridge to Uplisting
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall
Arch Therapeutics Launches Experts in Wound Care Program
Arch Therapeutics Provides Corporate Update
Arch Therapeutics to Present at the LD Micro Main Event
Arch Therapeutics Launches Coverage and Reimbursement Pilot
Arch Therapeutics Announces Appointment of Larry Hicks to the Board